Loading…
Loading…
research
CMAB Biopharma Inc. (CMAB), is a full-service contract development and manufacturing organization (CDMO) established in 2017, which is dedicated to providing process development and manufacturing services for biologic products. We provide bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. Our adaptable, service-oriented business enables clients to take their innovative concepts for tomorrow's medicines from DNA to clinical product today. Located in Suzhou's BioBAY Park, CMAB's manufacturing facility will provide services for the development of manufacturing process, analytical method, formulation, and the manufacture of biologic drug substances and drug products. Our initial facility will generate pre-clinical and early-stage clinical (Phase I/II) products, using manufacturing that follows global GMP standards, including those of the China National Medical Products Administration (NMPA), US Food & Drug Administration (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH standards. CMAB has quickly built up a team with strong expertise in the biologics CDMO industry. The founding CMAB management team have solid experience gained from international bio-pharmaceutical companies and have collectively delivered more than 100 CDMO projects resulting in at least 40 IND applications for biological drugs. Currently, CMAB has over 160 employees and targets expansion to a strength of more than 200 staff at the end of 2019. In January 2018, CMAB completed its series A financing of US$38 million, which was led by C-Bridge Capital and BioBAY, with I-Bridge Capital and Qianhai FoF fund joining the consortium. A series B financing round of US$34 million was secured in April 2018, led by CD Capital, with joint participation by C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed. Learn more about CMAB at our website: www.cmabbio.com or contact us directly at hello@cmabbio.com
CMAB Biopharma Inc. (CMAB), is a full-service contract development and manufacturing organization (CDMO) established in 2017, which is dedicated to providing process development and manufacturing services for biologic products. We provide bespoke development manufacturing services of antibodies and biologics for clients in China and across the globe. Our adaptable, service-oriented business enables clients to take their innovative concepts for tomorrow's medicines from DNA to clinical product today. Located in Suzhou's BioBAY Park, CMAB's manufacturing facility will provide services for the development of manufacturing process, analytical method, formulation, and the manufacture of biologic drug substances and drug products. Our initial facility will generate pre-clinical and early-stage clinical (Phase I/II) products, using manufacturing that follows global GMP standards, including those of the China National Medical Products Administration (NMPA), US Food & Drug Administration (21 CFR), European Medicines Agency (Eudralex), WHO, and harmonized PIC/S and ICH standards. CMAB has quickly built up a team with strong expertise in the biologics CDMO industry. The founding CMAB management team have solid experience gained from international bio-pharmaceutical companies and have collectively delivered more than 100 CDMO projects resulting in at least 40 IND applications for biological drugs. Currently, CMAB has over 160 employees and targets expansion to a strength of more than 200 staff at the end of 2019. In January 2018, CMAB completed its series A financing of US$38 million, which was led by C-Bridge Capital and BioBAY, with I-Bridge Capital and Qianhai FoF fund joining the consortium. A series B financing round of US$34 million was secured in April 2018, led by CD Capital, with joint participation by C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed. Learn more about CMAB at our website: www.cmabbio.com or contact us directly at hello@cmabbio.com
Represent this company? Request removal or email privacy@pitchcentric.com.
FAQs
If you have a concern about deliverability, AI quality, data privacy, or whether this will actually work for your specific situation, it's probably answered below.
Founder Solo gives you 50 AI pitches per month using the credit model (Standard pitches cost 1 credit, Enriched pitches cost 2). Founder Pro raises that to 200 credits per month and adds full Booking Probability access, unlimited Magic Match, Apollo enrichment credits, and data export capabilities. Both plans use the same credit system, so you can stretch your monthly budget further by using Standard-mode drafting.
Agency tiers have no base fee. You pay per managed client and per talent profile. Agency Standard is $199 per client per month; Agency Pro is $399 per client per month. Both add $39 per talent profile per month. Your own team's user seats are always free.
A talent profile represents one person (founder, executive, or spokesperson) you are booking onto podcasts. It includes their bio, topics, headshots, and outreach history. Team plans include 5 profiles; agency plans are pay-as-you-go.
Yes, at any time. Upgrades take effect immediately; downgrades apply at the end of the current billing period. Contact support if you need help migrating between plan families.
Every paid plan includes a 15-day free trial. Your card is saved at signup but you will not be charged until day 16. Cancel any time from your dashboard.
You keep access until the end of your current billing period. No charges after that. Your data is retained for 30 days in case you reactivate.
Yes. Select Annual on the pricing toggle and the discounted price is applied automatically at checkout. The annual price shown is the full year cost.
That is our Enterprise tier. Contact our sales team and we will build a custom plan with volume pricing, a dedicated account manager, and SLA guarantees.
